

Chan Harjivan, Visiting Fellow, Duke Margolis Institute for Health Policy



With more than 25 years of experience spanning public health, government, and the biopharmaceutical industry, Mr. Chan Harjivan has worked with the leadership of nearly every major pharmaceutical company, U.S. health agency, and global health organization to accelerate the development and delivery of lifesaving vaccines, therapeutics, and diagnostics.

His last full-time position was as a Special Assistant to the President in the White House, where reported directly to the President; overseeing vaccines, therapeutics, diagnostics, R&D, supply chain and response plans to strengthen the nation's readiness for biological threats through strategic policy coordination, interagency collaboration, and public-private partnerships.

In 2021 he co-founded SaponiQx, a next-generation vaccine adjuvant company valued at \$250 million on exit. Its key product, STIMULON™ QS-21 is a crucial component in vaccines such as GSK's Shingrix.

He was a key architect of Operation Warp Speed, the historic federal initiative that developed COVID-19 vaccine development and distribution, sitting side by side with the CEO and COO from its inception to close.

Chan was a Managing Director and Partner at Boston Consulting Group where he founded and led the Public Sector Health Practice; and prior to that, a Partner at PwC where he founded and led the Global Health Practice.

Mr. Harjivan has not previously testified before the Commission.